Actionable news
All posts from Actionable news
Actionable news in KITE: KITE PHARMA Inc,

Entry into a Material Definitive

On October26, 2015, Kite Pharma, Inc. (Kite) entered into a License and Research Agreement (the Agreement) with Alpine Immune Sciences, Inc. (AIS) pursuant to which AIS granted Kite an exclusive, worldwide license to research, develop and commercialize engineered autologous T cell therapies incorporating two programs from AIS transmembrane immunomodulatory protein (TIP) technology.

Under the terms of the Agreement, AIS will conduct initial research to deliver two program TIPs with certain pre-defined characteristics. Kite will then conduct further research on the program TIPs with the goal of demonstrating proof-of-concept. If successful, Kite would further engineer the program TIPs into certain chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates that would potentially enhance anti-tumor response.

Pursuant to the Agreement, Kite will pay AIS a $5.0 million upfront payment and additional payments to support AIS research. AIS will be...